Apollomics Inc. Class A Ordinary Shares (APLM) is a Healthcare · Biotechnology company listed on NASDAQ. Price $23.42 (+3.97%), Market cap $0.03B, 52-week low–high $3.93 ~ $36.65.
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting Er
Financial statements, price targets, institutional (13F) holdings and related news for Apollomics Inc. Class A Ordinary Shares are updated in real time on BlackAll Trade.
Apollomics Inc. Class A Ordinary Shares trades at $23.42 (+3.97%). Real-time quotes and charts are available on BlackAll Trade.
Apollomics Inc. Class A Ordinary Shares has a market cap of about $0.03B.
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhi